Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Date: January 11, 2021
Issue #:
1615Summary:
The oral polymerase acidic endonuclease inhibitor
baloxavir marboxil (Xofluza— Genentech) is now FDAapproved
for post-exposure prophylaxis of influenza
in patients ≥12 years old. Baloxavir was approved for
treatment of acute uncomplicated influenza in patients
≥12 years old in 2018.1 Two neuraminidase inhibitors
are FDA-approved for prophylaxis of influenza:
oseltamivi r(Tamiflu, and generics) in patients ≥1 year
old, and zanamivir(Relenza) in patients ≥5 years old.2
Unlike oseltamivir and zanamivir, baloxavir is not FDA-approved
for pre-exposure prophylaxis of influenza
during institutional or community outbreaks.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: baloxavir influenza Oseltamivir Relenza Tamiflu Xofluza Zanamivir Source Type: research
More News: Drugs & Pharmacology | Influenza | Oseltamivir | Outbreaks | Relenza | Tamiflu | Zanamivir